

Zachary T Bloomgarden

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9030981/publications.pdf>

Version: 2024-02-01

198
papers

3,973
citations

182225

30
h-index

169272

56
g-index

231
all docs

231
docs citations

231
times ranked

5462
citing authors

#	ARTICLE	IF	CITATIONS
1	The 5 th Annual Heart in Diabetes Conference (part 2). Journal of Diabetes, 2022, 14, 93-96.	0.8	0
2	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and Its Complications, 2022, 36, 108101.	1.2	23
3	The world congress on insulin resistance, diabetes, and cardiovascular disease (<scp>WCIRDC</scp>) Tj ETQq1 1 0.784314 rgBT /Ov	0.8	0
4	Biosimilar insulin concepts. Journal of Diabetes, 2022, 14, 231-235.	0.8	1
5	Learning by reading: A review of recent diabetes articles. Journal of Diabetes, 2022, 14, 301-305.	0.8	0
6	The Chinese Metabolic Management Centers. Journal of Diabetes, 2022, 14, 362-364.	0.8	0
7	Diabetes and stroke: An important complication. Journal of Diabetes, 2021, 13, 184-190.	0.8	16
8	Various and sundry recent publications. Journal of Diabetes, 2021, 13, 4-6.	0.8	0
9	<scp>COVID</scp>â€19 in the United States: Where are we now? Where have we been?. Journal of Diabetes, 2021, 13, 98-100.	0.8	1
10	Use of <scp>HbA1c</scp> in clinical practice: New insights. Journal of Diabetes, 2021, 13, 280-281.	0.8	0
11	Glycemic treatment: Further concepts. Journal of Diabetes, 2021, 13, 362-363.	0.8	0
12	Celiac disease: A global survey. Journal of Diabetes, 2021, 13, 446-447.	0.8	0
13	Developments in type 1 and type 2 diabetes. Journal of Diabetes, 2021, 13, 530-531.	0.8	2
14	Type 2 diabetes in the young in South Asia: Clinical heterogeneity and need for aggressive public health measures. Journal of Diabetes, 2021, 13, 610-612.	0.8	0
15	Rationale for glycemic control to improve cardiovascular outcome: Lessons from east and west. Journal of Diabetes, 2021, 13, 698-700.	0.8	1
16	Presentations at the 81st scientific sessions of the <scp>American Diabetes Association</scp> (<scp>ADA</scp>), Part 1. Journal of Diabetes, 2021, 13, 768-769.	0.8	0
17	Presentations at the 81st scientific sessions of the American Diabetes Association , part 2. Journal of Diabetes, 2021, 13, 844-846.	0.8	0
18	Comparative Safety of Dipeptidyl Peptidaseâ€4 Inhibitors and Sudden Cardiac Arrest and Ventricular Arrhythmia: Populationâ€Based Cohort Studies. Clinical Pharmacology and Therapeutics, 2021, , .	2.3	3

#	ARTICLE	IF	CITATIONS
19	The journal of diabetes is adopting open access. Journal of Diabetes, 2021, , .	0.8	0
20	The Fifth Annual Heart in Diabetes Conference (Part 1). Journal of Diabetes, 2021, 13, 946-948.	0.8	0
21	Sodium-glucose cotransporter 2 inhibitors for macroalbuminuria: A new indication. Journal of Diabetes, 2020, 12, 8-9.	0.8	0
22	Insulin resistance: looking back, looking forward. Journal of Diabetes, 2020, 12, 184-186.	0.8	1
23	The Jiangnan diet, a healthy diet pattern for Chinese. Journal of Diabetes, 2020, 12, 365-371.	0.8	50
24	The ADA 2020 virtual poster hall. Journal of Diabetes, 2020, 12, 778-780.	0.8	0
25	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm “2020 Executive Summary. Endocrine Practice, 2020, 26, 1196-1224.	1.1	117
26	New insights into the older hypoglycemic agents in type 2 diabetes therapy. Journal of Diabetes, 2020, 12, 844-847.	0.8	0
27	Does glycemic control affect outcome of COVID-19?. Journal of Diabetes, 2020, 12, 868-869.	0.8	6
28	Diabetes during the COVID-19 pandemic: A global call to reconnect with patients and emphasize lifestyle changes and optimize glycemic and blood pressure control. Journal of Diabetes, 2020, 12, 556-557.	0.8	16
29	Early Life Famine Exposure, Ideal Cardiovascular Health Metrics, and Risk of Incident Diabetes: Findings From the 4C Study. Diabetes Care, 2020, 43, 1902-1909.	4.3	36
30	Tweeting, tweeting. Journal of Diabetes, 2020, 12, 424-425.	0.8	0
31	Diabetes and COVID-19. Journal of Diabetes, 2020, 12, 347-348.	0.8	112
32	Which person with diabetes should receive cardioprotective glucose-lowering medicines?. Journal of Diabetes, 2020, 12, 352-353.	0.8	0
33	Paradigm shift in the management of DM & CVD “preventing the next CV event. Journal of Diabetes, 2020, 12, 630-632.	0.8	0
34	Management and prevention of cardiovascular disease for type 2 diabetes: Integrating the diabetes management recommendations of AACE, ADA, EASD, AHA, ACC, and ESC. American Journal of Preventive Cardiology, 2020, 1, 100007.	1.3	2
35	Andrew Jay Drexler, in memoriam. Journal of Diabetes, 2020, 12, 712-713.	0.8	0
36	The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety. Cardiovascular Diabetology, 2020, 19, 25.	2.7	16

#	ARTICLE	IF	CITATIONS
37	Use of online information in diabetes. <i>Journal of Diabetes</i> , 2020, 12, 268-269.	0.8	0
38	Is the type of diabetes treatment relevant to outcome of COVID-19?. <i>Journal of Diabetes</i> , 2020, 12, 486-487.	0.8	5
39	Prognostic Significance of Long-term HbA1c Variability for All-Cause Mortality in the ACCORD Trial. <i>Diabetes Care</i> , 2020, 43, 1185-1190.	4.3	66
40	The heart in diabetes meeting. <i>Journal of Diabetes</i> , 2019, 11, 840-841.	0.8	0
41	Ideal Cardiovascular Health Metrics and Major Cardiovascular Events in Patients With Prediabetes and Diabetes. <i>JAMA Cardiology</i> , 2019, 4, 874.	3.0	70
42	ADA2019. <i>Journal of Diabetes</i> , 2019, 11, 778-780.	0.8	0
43	Introduction to the 2nd Heart in Diabetes (HiD) Meeting. <i>Journal of Diabetes</i> , 2019, 11, 599-600.	0.8	1
44	Implications of the recent CVOTs in type 2 diabetes: The right place for DPP-IV inhibitors today. <i>Diabetes Research and Clinical Practice</i> , 2019, 157, 107906.	1.1	1
45	Acupuncture for painful diabetic neuropathy. <i>Journal of Diabetes</i> , 2019, 11, 924-924.	0.8	1
46	Diabetes phenotypes: Beyond IDDM vs NIDDM. <i>Journal of Diabetes</i> , 2019, 11, 698-699.	0.8	1
47	Predictive Value of Fasting Glucose, Postload Glucose, and Hemoglobin A1c on Risk of Diabetes and Complications in Chinese Adults. <i>Diabetes Care</i> , 2019, 42, 1539-1548.	4.3	102
48	Glucokinase and the potential of glucokinase activation in type 2 diabetes. <i>Journal of Diabetes</i> , 2019, 11, 626-627.	0.8	1
49	What constitutes good research?. <i>Journal of Diabetes</i> , 2019, 11, 502-504.	0.8	0
50	Beyond HbA1c, second take. <i>Journal of Diabetes</i> , 2019, 11, 416-417.	0.8	3
51	Evolution of type 2 diabetes mellitus treatment approaches. <i>Journal of Diabetes</i> , 2019, 11, 4-6.	0.8	2
52	Notes from the world congress on insulin resistance, diabetes, and cardiovascular disease. <i>Journal of Diabetes</i> , 2019, 11, 258-260.	0.8	0
53	Lipids as risk markers for type 2 diabetes. <i>Journal of Diabetes</i> , 2019, 11, 176-178.	0.8	2
54	Fournier's gangrene and sodium-glucose cotransporter 2 inhibitors: Is there a causal association?. <i>Journal of Diabetes</i> , 2019, 11, 340-341.	0.8	8

#	ARTICLE	IF	CITATIONS
55	Supplements. Journal of Diabetes, 2019, 11, 100-101.	0.8	0
56	Transition from hospital to outpatient diabetes care. Journal of Diabetes, 2018, 10, 538-540.	0.8	0
57	American College of Physicians diabetes guidelines attempt to turn back the clock, conflating good HbA1c with hypoglycemia. Journal of Diabetes, 2018, 10, 618-620.	0.8	6
58	Diabetes and branched-chain amino acids: what is the link?. Journal of Diabetes, 2018, 10, 350-352.	0.8	153
59	Metabolic memory: Evolving concepts. Journal of Diabetes, 2018, 10, 186-187.	0.8	34
60	Journal of Diabetes: Ushering in Volume 10. Journal of Diabetes, 2018, 10, 4-5.	0.8	12
61	The kidney and cardiovascular outcome trials. Journal of Diabetes, 2018, 10, 88-89.	0.8	37
62	How does CKD affect HbA1c?. Journal of Diabetes, 2018, 10, 270-270.	0.8	18
63	Talks and tweets from the ADA. Journal of Diabetes, 2018, 10, 812-815.	0.8	1
64	World congress on insulin resistance, diabetes and cardiovascular disease. Journal of Diabetes, 2018, 10, 776-777.	0.8	2
65	Discordance between HbA1c and glycemia. Journal of Diabetes, 2018, 10, 908-910.	0.8	9
66	Adherence and diabetes. Journal of Diabetes, 2018, 10, 692-694.	0.8	1
67	Temporal trends in ischemic stroke and anticoagulation therapy for non-valvular atrial fibrillation: effect of diabetes. Journal of Diabetes, 2017, 9, 115-122.	0.8	8
68	Chelation for diabetes complications: a neglected approach?. Journal of Diabetes, 2017, 9, 318-319.	0.8	0
69	Diabetes and tuberculosis: an important relationship. Journal of Diabetes, 2017, 9, 640-643.	0.8	7
70	Non-alcoholic fatty liver disease and type 2 diabetes: Importance of glycemic control. Journal of Diabetes, 2017, 9, 722-723.	0.8	2
71	Is insulin the preferred treatment for HbA1c >9%?. Journal of Diabetes, 2017, 9, 814-816.	0.8	6
72	Diabetes treatment over age 65: is worse control really better?. Journal of Diabetes, 2017, 9, 428-430.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Upper extremity arthropathy in diabetes. <i>Journal of Diabetes</i> , 2017, 9, 542-543.	0.8	0
74	What strategies are implied by STRATEGY?. <i>Science China Life Sciences</i> , 2017, 60, 319-320.	2.3	0
75	Is HbA1c <7% a Marker of Poor Performance in Individuals >65 Years Old?. <i>Diabetes Care</i> , 2017, 40, 526-528.	4.3	12
76	The <i>Journal of Diabetes</i> in its ninth year. <i>Journal of Diabetes</i> , 2017, 9, 214-214.	0.8	0
77	Response to Comment on Bloomgarden et al. Is HbA1c <7% a Marker of Poor Performance in Individuals >65 Years Old? <i>Diabetes Care</i> 2017;40:526-528. <i>Diabetes Care</i> , 2017, 40, e154-e154.	4.3	0
78	Concomitant Diabetes and Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1336-1338.	1.2	1
79	Dipeptidyl peptidase-4 inhibitor approaches. <i>Journal of Diabetes</i> , 2017, 9, 5-7.	0.8	2
80	Fear of hypoglycemia. <i>Journal of Diabetes</i> , 2017, 9, 108-110.	0.8	12
81	American Society of Clinical Oncology Summit on Addressing Obesity Through Multidisciplinary Provider Collaboration: Key Findings and Recommendations for Action. <i>Obesity</i> , 2017, 25, S34-S39.	1.5	12
82	AACE Position Statement on the use of follow-on Biologics and Biosimilars for Endocrine Diseases. <i>Endocrine Practice</i> , 2017, 23, 1345-1349.	1.1	5
83	Type 2 treatments for type 1 diabetes. <i>Journal of Diabetes</i> , 2016, 8, 599-601.	0.8	2
84	Approaches to treatment 2: Comparison of American Association of Clinical Endocrinologists (AACE) and American Diabetes Association (ADA) type 2 diabetes treatment guidelines. <i>Journal of Diabetes</i> , 2016, 8, 4-6.	0.8	15
85	Treatment: Concepts and new developments. <i>Journal of Diabetes</i> , 2016, 8, 297-299.	0.8	0
86	Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis. <i>Journal of Diabetes</i> , 2016, 8, 175-176.	0.8	8
87	Glycemic control and the heart: it matters how you get there. <i>Journal of Diabetes</i> , 2016, 8, 453-454.	0.8	3
88	Questioning glucose measurements used in the International Diabetes Federation (IDF) Atlas. <i>Journal of Diabetes</i> , 2016, 8, 746-747.	0.8	10
89	A Diabetes-Atrial Fibrillation Conundrum. <i>Journal of the American College of Cardiology</i> , 2016, 67, 248-250.	1.2	3
90	Helping people with diabetes to exercise. <i>Journal of Diabetes</i> , 2015, 7, 150-152.	0.8	4

#	ARTICLE	IF	CITATIONS
91	Diabetes and cancer: Findings from the <sc>REACTION</sc> study (J Diabetes, 2015, 7, 143-144).	0.8	30
92	Self-monitoring of blood glucose for type 2 diabetes. Journal of Diabetes, 2015, 7, 593-594.	0.8	4
93	Advances in sleep research (J Diabetes, 2015, 7, 8-9).	0.8	0
94	Individualizing therapy: Do we have the tools to do it? (J Diabetes, 2015, 7, 747-748).	0.8	1
95	American Association of Clinical Endocrinologists and American College of Endocrinology "Clinical Practice Guidelines for Developing A Diabetes Mellitus Comprehensive Care Plan " 2015 " Executive Summary. Endocrine Practice, 2015, 21, 413-437.	1.1	359
96	Approaches to treatment 1: How is type 2 diabetes actually treated?. Journal of Diabetes, 2015, 7, 747-748.	0.8	1
97	Sodium-glucose cotransporter 2 inhibitors and renal function (J Diabetes, 2015, 7, 747-748).	0.8	1
98	Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). American Heart Journal, 2015, 170, 675-682.e8.	1.2	128
99	The Future of Diabetes. Canadian Journal of Diabetes, 2015, 39, 204-205.	0.4	1
100	Determinants of adherence to diabetes treatment. Journal of Diabetes, 2015, 7, 864-871.	0.8	46
101	Metformin and renal insufficiency "is 45, or even 30, the new 60?. Nature Reviews Endocrinology, 2015, 11, 693-694.	4.3	1
102	New approaches to wound healing for diabetes (J Diabetes, 2015, 7, 435-436).	0.8	1
103	Afrezza: Some questions about a new approach to prandial insulin (J Diabetes, 2015, 7, 489-490).	0.8	1
104	Association is not causation, particularly with "adjustment" (J Diabetes, 2015, 7, 435-436).	0.8	1
105	Cardiovascular safety trials: Be careful what you wish for (J Diabetes, 2015, 7, 435-436).	0.8	1
106	Cohort profile: Risk evaluation of cancers in <sc>C</sc>hinese diabetic individuals: a longitudinal (<sc>REACTION</sc>) study (J Diabetes, 2015, 7, 435-436).	0.8	147
107	Lessons from glargine trials: What is the goal fasting glucose with basal insulin? (Diabetes, 2014, 6, 271-273).	0.8	3
108	Is glycemic control a quinidine-like intervention? (J Diabetes, 2014, 6, 271-273).	0.8	1

#	ARTICLE	IF	CITATIONS
127	World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease. <i>Diabetes Care</i> , 2011, 34, e126-e131.	4.3	5
128	Troubling ethical questions from gestational diabetes trial. <i>Journal of Diabetes</i> , 2010, 2, 1-4.	0.8	4
129	Liraglutide and calcitonin. <i>Journal of Diabetes</i> , 2010, 2, 223-224.	0.8	2
130	The Avandia debate: An unhappy conclusion. <i>Journal of Diabetes</i> , 2010, 2, 221-222.	0.8	3
131	Blood Pressure and Diabetic Nephropathy. <i>Diabetes Care</i> , 2010, 33, e30-e35.	4.3	7
132	Cardiovascular Disease in Diabetes. <i>Diabetes Care</i> , 2010, 33, e49-e54.	4.3	22
133	Incretin Concepts. <i>Diabetes Care</i> , 2010, 33, e20-e25.	4.3	10
134	Type 1 Diabetes and Hypoglycemia. <i>Diabetes Care</i> , 2009, 32, e1-e4.	4.3	0
135	Topics in Type 2 Diabetes and Insulin Resistance. <i>Diabetes Care</i> , 2009, 32, e13-e19.	4.3	1
136	Diabetes Treatment. <i>Diabetes Care</i> , 2009, 32, e25-e30.	4.3	7
137	Cardiovascular Disease, Neuropathy, and Retinopathy. <i>Diabetes Care</i> , 2009, 32, e64-e68.	4.3	9
138	A1C: Recommendations, Debates, and Questions. <i>Diabetes Care</i> , 2009, 32, e141-e147.	4.3	55
139	Nephropathy and Other Topics. <i>Diabetes Care</i> , 2009, 32, e94-e98.	4.3	0
140	Recent cardiovascular trials: What are the drivers of benefit and adverse effect?. <i>Journal of Diabetes</i> , 2009, 1, 227-229.	0.8	1
141	Approaches to Treatment of Pre-Diabetes and Obesity and Promising New Approaches to Type 2 Diabetes. <i>Diabetes Care</i> , 2008, 31, 1461-1466.	4.3	13
142	Diabetes and Obesity: Part 2. <i>Diabetes Care</i> , 2008, 31, 176-182.	4.3	2
143	Diabetic Nephropathy. <i>Diabetes Care</i> , 2008, 31, 823-827.	4.3	19
144	What role will 'gliptins' play in glycemic control?. <i>Cleveland Clinic Journal of Medicine</i> , 2008, 75, 305-310.	0.6	15

#	ARTICLE	IF	CITATIONS
145	Gut Hormones, Obesity, Polycystic Ovarian Syndrome, Malignancy, and Lipodystrophy Syndromes. <i>Diabetes Care</i> , 2007, 30, 1934-1939.	4.3	5
146	Prevention of Cardiovascular Disease. <i>Diabetes Care</i> , 2007, 30, 423-431.	4.3	3
147	Screening for and managing diabetic retinopathy: Current approaches. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, S8-S14.	0.5	55
148	Does a structured patient education program improve glycemic control in individuals with type 2 diabetes mellitus?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 390-391.	2.9	1
149	The Avandia Debate. <i>Diabetes Care</i> , 2007, 30, 2401-2408.	4.3	29
150	Diabetic Neuropathy. <i>Diabetes Care</i> , 2007, 30, 1027-1032.	4.3	15
151	Type 1 Diabetes and Glucose Monitoring. <i>Diabetes Care</i> , 2007, 30, 2965-2971.	4.3	6
152	Exploring Treatment Strategies for Type 2 Diabetes. <i>Diabetes Care</i> , 2007, 30, 2737-2745.	4.3	21
153	Diabetes and Obesity. <i>Diabetes Care</i> , 2007, 30, 3145-3151.	4.3	7
154	Diabetic Retinopathy and Diabetic Neuropathy. <i>Diabetes Care</i> , 2007, 30, 760-765.	4.3	17
155	Achieving Glycemic Goals in Type 2 Diabetes. <i>Diabetes Care</i> , 2007, 30, 174-180.	4.3	11
156	Insulin Resistance, Dyslipidemia, and Cardiovascular Disease. <i>Diabetes Care</i> , 2007, 30, 2164-2170.	4.3	50
157	Insulin Resistance Concepts. <i>Diabetes Care</i> , 2007, 30, 1320-1326.	4.3	34
158	Measures of Insulin Sensitivity. <i>Clinics in Laboratory Medicine</i> , 2006, 26, 611-633.	0.7	45
159	Lower Baseline Glycemia Reduces Apparent Oral Agent Glucose-Lowering Efficacy: A meta-regression analysis. <i>Diabetes Care</i> , 2006, 29, 2137-2139.	4.3	204
160	Glycemic Treatment in Type 1 and Type 2 Diabetes. <i>Diabetes Care</i> , 2006, 29, 2549-2555.	4.3	4
161	Weight Control in Individuals With Diabetes. <i>Diabetes Care</i> , 2006, 29, 2749-2754.	4.3	4
162	Developments in diabetes and insulin resistance. <i>Diabetes Care</i> , 2006, 29, 161-7.	4.3	6

#	ARTICLE	IF	CITATIONS
163	Cardiovascular disease. <i>Diabetes Care</i> , 2006, 29, 1160-6.	4.3	0
164	Diabetic Nephropathy. <i>Diabetes Care</i> , 2005, 28, 745-751.	4.3	36
165	2nd International Symposium on Triglycerides and HDL: Metabolic syndrome. <i>Diabetes Care</i> , 2005, 28, 2577-2584.	4.3	8
166	Inflammation, Atherosclerosis, and Aspects of Insulin Action. <i>Diabetes Care</i> , 2005, 28, 2312-2319.	4.3	51
167	Insulin Resistance: Causes and Consequences. <i>International Review of Neurobiology</i> , 2005, 65, 1-24.	0.9	13
168	Approaching Treatment of the Insulin Resistance Syndrome. <i>Metabolic Syndrome and Related Disorders</i> , 2005, 3, 328-331.	0.5	1
169	Concepts of Insulin Resistance. <i>Metabolic Syndrome and Related Disorders</i> , 2005, 3, 284-293.	0.5	10
170	Diabetic Retinopathy and Neuropathy. <i>Diabetes Care</i> , 2005, 28, 963-970.	4.3	21
171	Thiazolidinediones. <i>Diabetes Care</i> , 2005, 28, 488-493.	4.3	30
172	Insulin Resistance in Children and in the Polycystic Ovarian Syndrome. <i>Metabolic Syndrome and Related Disorders</i> , 2005, 3, 294-304.	0.5	1
173	Transplantation and Islet Topics. <i>Diabetes Care</i> , 2005, 28, 213-219.	4.3	2
174	Clinical Diabetic Neuropathy. <i>Diabetes Care</i> , 2005, 28, 2968-2974.	4.3	17
175	Second World Congress on the Insulin Resistance Syndrome: Insulin resistance syndrome and nonalcoholic fatty liver disease. <i>Diabetes Care</i> , 2005, 28, 1518-1523.	4.3	41
176	Cardiovascular Complications of Insulin Resistance. <i>Metabolic Syndrome and Related Disorders</i> , 2005, 3, 305-315.	0.5	2
177	Non-Alcoholic Fatty Liver Disease and Malignancy as Complications of Insulin Resistance. <i>Metabolic Syndrome and Related Disorders</i> , 2005, 3, 316-327.	0.5	3
178	Aspects of Blood Pressure, Lipid, and Glycemic Treatment. <i>Diabetes Care</i> , 2004, 27, 264-269.	4.3	5
179	Inpatient Diabetes Control: Rationale. <i>Diabetes Care</i> , 2004, 27, 2074-2080.	4.3	7
180	Dyslipidemia and the Metabolic Syndrome. <i>Diabetes Care</i> , 2004, 27, 3009-3016.	4.3	25

#	ARTICLE	IF	CITATIONS
181	Type 2 Diabetes in the Young: The evolving epidemic. <i>Diabetes Care</i> , 2004, 27, 998-1010.	4.3	198
182	Diabetes Complications. <i>Diabetes Care</i> , 2004, 27, 1506-1514.	4.3	59
183	Glycemic Treatment: Control of glycemia. <i>Diabetes Care</i> , 2004, 27, 1227-1234.	4.3	9
184	Inpatient Diabetes Control: Approaches to treatment. <i>Diabetes Care</i> , 2004, 27, 2272-2277.	4.3	9
185	Consequences of Diabetes: Cardiovascular disease. <i>Diabetes Care</i> , 2004, 27, 1825-1831.	4.3	20
186	Inflammation and Insulin Resistance. <i>Diabetes Care</i> , 2003, 26, 1619-1623.	4.3	46
187	Fat Metabolism and Diabetes: 2003 American Diabetes Association Postgraduate Course. <i>Diabetes Care</i> , 2003, 26, 2198-2203.	4.3	5
188	Diabetes Issues in Women and Children: Polycystic ovary syndrome. <i>Diabetes Care</i> , 2003, 26, 2457-2463.	4.3	7
189	American Association of Clinical Endocrinologists (AACE) Consensus Conference on the Insulin Resistance Syndrome: 25-26 August 2002, Washington, DC. <i>Diabetes Care</i> , 2003, 26, 1297-1303.	4.3	66
190	Prevention of Obesity and Diabetes. <i>Diabetes Care</i> , 2003, 26, 3172-3178.	4.3	26
191	Approaches to Cardiovascular Disease and Its Treatment. <i>Diabetes Care</i> , 2003, 26, 3342-3348.	4.3	10
192	Inflammation and Insulin Resistance. <i>Diabetes Care</i> , 2003, 26, 1922-1926.	4.3	74
193	Adiposity and Diabetes. <i>Diabetes Care</i> , 2002, 25, 2342-2349.	4.3	24
194	Treatment Issues in Type 2 Diabetes. <i>Diabetes Care</i> , 2002, 25, 614-619.	4.3	4
195	Treatment Issues in Type 1 Diabetes. <i>Diabetes Care</i> , 2002, 25, 230-238.	4.3	14
196	Neuropathy, Womens' Health, and Socioeconomic Aspects of Diabetes. <i>Diabetes Care</i> , 2002, 25, 1085-1094.	4.3	5
197	Obesity, Hypertension, and Insulin Resistance. <i>Diabetes Care</i> , 2002, 25, 2088-2097.	4.3	53
198	The 2022 American Diabetes Association Meeting. <i>Journal of Diabetes</i> , 0, , .	0.8	1